Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Role of glioblastoma stem cells in cancer therapeutic resistance: a perspective on antineoplastic agents from natural sources and chemical derivatives

Full text
Alves, Ana Laura V. [1] ; Gomes, Izabela N. F. [1] ; Carloni, Adriana C. [1] ; Rosa, Marcela N. [1] ; da Silva, Luciane S. [1] ; Evangelista, Adriane F. [1] ; Reis, Rui Manuel [1, 2, 3] ; Silva, Viviane Aline O. [1]
Total Authors: 8
[1] Barretos Canc Hosp, Mol Oncol Res Ctr, Rua Antenor Duarte Villela 1331, BR-14784400 Barretos, SP - Brazil
[2] ICVS 3Bs PT Govt Associate Lab, P-4806909 Braga - Portugal
[3] Univ Minho, Life & Hlth Sci Res Inst ICVS, Sch Med, P-4710057 Braga - Portugal
Total Affiliations: 3
Document type: Review article
Source: STEM CELL RESEARCH & THERAPY; v. 12, n. 1 MAR 24 2021.
Web of Science Citations: 0

Glioblastoma (GBM) is the highest-grade form of glioma, as well as one of the most aggressive types of cancer, exhibiting rapid cellular growth and highly invasive behavior. Despite significant advances in diagnosis and therapy in recent decades, the outcomes for high-grade gliomas (WHO grades III-IV) remain unfavorable, with a median overall survival time of 15-18months. The concept of cancer stem cells (CSCs) has emerged and provided new insight into GBM resistance and management. CSCs can self-renew and initiate tumor growth and are also responsible for tumor cell heterogeneity and the induction of systemic immunosuppression. The idea that GBM resistance could be dependent on innate differences in the sensitivity of clonogenic glial stem cells (GSCs) to chemotherapeutic drugs/radiation prompted the scientific community to rethink the understanding of GBM growth and therapies directed at eliminating these cells or modulating their stemness. This review aims to describe major intrinsic and extrinsic mechanisms that mediate chemoradioresistant GSCs and therapies based on antineoplastic agents from natural sources, derivatives, and synthetics used alone or in synergistic combination with conventional treatment. We will also address ongoing clinical trials focused on these promising targets. Although the development of effective therapy for GBM remains a major challenge in molecular oncology, GSC knowledge can offer new directions for a promising future. (AU)

FAPESP's process: 17/22305-9 - Study of biomarkers of cetuximab response and perspective of application of anti-EGFR combi-molecules in solid tumors
Grantee:Izabela Natalia Faria Gomes
Support Opportunities: Scholarships in Brazil - Doctorate
FAPESP's process: 19/05142-4 - Characterization of the biological effect of semisynthetic compound derived from Euphorbia tirucalli in vitro and in vivo, from the establishment of patients-derived xenografts with gastrointestinal tract tumors
Grantee:Ana Laura Vieira Alves
Support Opportunities: Scholarships in Brazil - Doctorate